Inside the Fund
So far in 2015, the fund is up about 11%, which is in-line with the iShares NASDAQ Biotechnology Index (IBB) and well above the S&P 500 index, which is up about 3%.
Nearly 30% of the fund’s portfolio is comprised of its top 5 holdings.
|Symbol||Stock||Portfolio Weight||YTD Performance|
The Bottom Line
Sign up for Advisor Access
Receive email updates about best performers, news, CE accredited webcasts and more.